Evidence map›Paper›PMID 35782051›Full record

ArticleOncotarget2022

Role of germline variants in the metastasis of breast carcinomas.

Ángela Santonja, Aurelio A Moya-García, Nuria Ribelles, Begoña Jiménez-Rodríguez, Bella Pajares, Cristina E Fernández-De Sousa, Elísabeth Pérez-Ruiz, María Del Monte-Millán, Manuel Ruiz-Borrego, Juan de la Haba and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Ángela SantonjaInstituto de Investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Spain.
Aurelio A Moya-GarcíaLaboratorio de Biología Molecular del Cáncer, Centro de Investigaciones Médico-Sanitarias (CIMES), Universidad de Málaga, Málaga, Spain.
Nuria RibellesUnidad de Gestión Clínica Intercentro de Oncología, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, Spain.
Begoña Jiménez-RodríguezUnidad de Gestión Clínica Intercentro de Oncología, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, Spain.
Bella PajaresUnidad de Gestión Clínica Intercentro de Oncología, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Málaga, Spain.
Cristina E Fernández-De SousaInstituto de Investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Spain.
Elísabeth Pérez-RuizMedical Oncology Service, Hospital Costa del Sol, Marbella, Málaga, Spain.
María Del Monte-MillánCentro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.
Manuel Ruiz-BorregoMedical Oncology Service, Hospital Virgen del Rocío, Sevilla, Spain.
Juan de la HabaCentro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.
Pedro Sánchez-RoviraDepartment of Oncology, Complejo Hospitalario de Jaén, Jaén, Spain.
Atocha RomeroMolecular Oncology Laboratory, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Anna González-NeiraHuman Genotyping-CEGEN Unit, Human Cancer Genetics Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Ana LluchCentro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, Spain.
Emilio AlbaLaboratorio de Biología Molecular del Cáncer, Centro de Investigaciones Médico-Sanitarias (CIMES), Universidad de Málaga, Málaga, Spain.
Instituto de Investigación Biomédica de Málaga · ESCentro de Investigación Biomédica en Red de Cáncer · ESUniversidad de Málaga · ESComplejo Hospitalario de Jaén · ESHospital Costa del Sol · ESHospital Universitario Virgen del Rocío · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESInstituto de Salud Carlos III · ESSpanish National Cancer Research Centre · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most cancer-related deaths in breast cancer patients are associated with metastasis, a multistep, intricate process that requires the cooperation of tumour cells, tumour microenvironment and metastasis target tissues. It is accepted that metastasis does not depend on the tumour characteristics but the host's genetic makeup. However, there has been limited success in determining the germline genetic variants that influence metastasis development, mainly because of the limitations of traditional genome-wide association studies to detect the relevant genetic polymorphisms underlying complex phenotypes. In this work, we leveraged the extreme discordant phenotypes approach and the epistasis networks to analyse the genotypes of 97 breast cancer patients. We found that the host's genetic makeup facilitates metastases by the dysregulation of gene expression that can promote the dispersion of metastatic seeds and help establish the metastatic niche-providing a congenial soil for the metastatic seeds.

Indexed as

Germ-Line MutationNeoplasm MetastasisBreast NeoplasmsGenome-Wide Association StudyHumansTumor Microenvironmentbreast cancerepistasisgermline variantsnetwork analysisseed and soil

Identifiers

PMID35782051
PMCPMC9245581
OpenAlexW4283758107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.